2003 Publications Abstracts

DOMAIN SPECIFICITY OF AUTOANTIBODIES TO BETA2-GLYCOPROTEIN I IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME ENROLLED IN A PHASE 1/2 TRIAL WITH LJP 1082
Matthew D. Linnik, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003

SLE PATIENTS WITH SUSTAINED REDUCTIONS IN ANTI-DSDNA ANTIBODIES HAVE A REDUCED RISK OF RENAL FLARE AND MAJOR SLE FLARE
Matthew D Linnik, et al.
Presented at the
67^th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003

RESULTS OF A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PHASE 1/2 CLINICAL TRIAL (RCT) TO ASSESS THE SAFETY AND TOLERABILITY OF LJP 1082 IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
Arash Horizon, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003

SMALL MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY AND AUTOIMMUNE DISORDERS
Luisa Salter-Cid, et al
Presented at
Inflammatory Processes in Drug Discovery
Philadelphia, PA
September 22-23, 2003

IN VIVO CHARACTERIZATION OF BIOCONJUGATE B CELL TOLERAGENS WITH SPECIFICITY FOR AUTOANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME
Cockerill KA, et al.
Published in
International Immunopharmacology, 2003
Volume 3, Issue 12: pp 1667-1675

MULTIVALENT POLY(ETHYLENE GLYCOL)-CONTAINING CONJUGATES FOR IN VIVO ANTIBODY SUPPRESSION
Dave Jones, et al
Published in
Bioconjugate Chemistry, 2003
Volume 14, Issue 6: 1067-1076